A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

Healthy Clinical Trial

Official title:

A Phase 1, Single-Center, Randomized, 3-Period Crossover Study to Evaluate the Relative Bioavailability of WTX101 in Healthy Subjects After Single Dose Administration of a Non-Coated Formulation With and Without a Proton Pump Inhibitor and With a Proton Pump Inhibitor With and Without Food

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05319899
• Other study ID #: WTX101-101
• Secondary ID: CA12887
• Status: Completed
• Phase: Phase 1
• Start date: January 20, 2014
• Est. completion date: March 24, 2014

Study information

• Verified date: September 2022
• Source: Alexion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was single-center, open-label, randomized, 3-period, 3-treatment, 6-sequence crossover study evaluating the PK of single doses of WTX101 in healthy participants based on the measurement of plasma total Molybdenum.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: March 24, 2014
• Est. primary completion date: March 24, 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years to 55 Years

Eligibility

Inclusion Criteria:

• Non-smoker

• Medically healthy with no clinically significant laboratory profiles, vital signs, or electrocardiograms.

• Body mass index = 18 and = 32.0 kilograms/meter squared.

• Willing and able to adhere to contraception requirements.

Exclusion Criteria:

• Participant was mentally or legally incapacitated

• History or presence of clinically significant medical or psychiatric condition or disease.

• History of any illness that might have interfered with drug absorption.

• History or presence of hypersensitivity or idiosyncratic reaction to the study medications, study medication excipients.

• History or presence of alcoholism or drug abuse.

• Female participants who were pregnant or lactating.

• Positive results at screening for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus.

• Serum ceruloplasmin and copper values outside of the normal range at screening.

• On a diet incompatible with the on-study diet within the 28 days prior to the first ALXN1840 dose and throughout the study; unable to consume the contents of a high-fat breakfast.

• Participation in a previous clinical trial with ALXN1840.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• ALXN1840
ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
• Omeprazole
Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.

Locations

Country	Name	City	State
United States	Clinical Trial Site	Lincoln	Nebraska

Sponsors (1)

Lead Sponsor	Collaborator
Alexion

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo)	AUC0-t was calculated by the linear trapezoidal method.	Predose (0 hour) up to 192 hours postdose
Primary	Maximum Measured Plasma Concentration (Cmax) of Total Mo		Predose (0 hour) up to 192 hours postdose
Primary	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with the study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A TEAE was defined as an AE that started or worsened at the time of or after study drug administration. An AE that occurred during the washout period between drugs was considered treatment emergent to the last drug given. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.	Day 1 through 14 days following final dose (up to Day 43)